CN113789299B - 一种脐血nk细胞的体外增殖培养基、体外培养试剂盒和体外培养方法 - Google Patents
一种脐血nk细胞的体外增殖培养基、体外培养试剂盒和体外培养方法 Download PDFInfo
- Publication number
- CN113789299B CN113789299B CN202111208066.6A CN202111208066A CN113789299B CN 113789299 B CN113789299 B CN 113789299B CN 202111208066 A CN202111208066 A CN 202111208066A CN 113789299 B CN113789299 B CN 113789299B
- Authority
- CN
- China
- Prior art keywords
- cells
- vitro
- cord blood
- culture medium
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000338 in vitro Methods 0.000 title claims abstract description 73
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 66
- 210000004700 fetal blood Anatomy 0.000 title claims abstract description 53
- 230000035755 proliferation Effects 0.000 title claims abstract description 45
- 239000001963 growth medium Substances 0.000 title claims abstract description 38
- 238000012136 culture method Methods 0.000 title abstract description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 40
- 238000012258 culturing Methods 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 15
- 229920001917 Ficoll Polymers 0.000 claims abstract description 7
- 210000005087 mononuclear cell Anatomy 0.000 claims description 23
- 239000002609 medium Substances 0.000 claims description 21
- 230000004913 activation Effects 0.000 claims description 19
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 16
- 230000003213 activating effect Effects 0.000 claims description 16
- 102000055277 human IL2 Human genes 0.000 claims description 16
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- BGFHMYJZJZLMHW-UHFFFAOYSA-N 4-[2-[[2-(1-benzothiophen-3-yl)-9-propan-2-ylpurin-6-yl]amino]ethyl]phenol Chemical compound N1=C(C=2C3=CC=CC=C3SC=2)N=C2N(C(C)C)C=NC2=C1NCCC1=CC=C(O)C=C1 BGFHMYJZJZLMHW-UHFFFAOYSA-N 0.000 claims description 7
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims description 7
- 101710132602 Peroxidase 5 Proteins 0.000 claims description 7
- 102000056003 human IL15 Human genes 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000010899 nucleation Methods 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 abstract description 6
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 abstract description 6
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 abstract description 6
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 abstract description 6
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 abstract description 6
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 abstract description 6
- 102000005962 receptors Human genes 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 abstract description 3
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 abstract description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract description 3
- 230000005909 tumor killing Effects 0.000 abstract description 3
- 239000011248 coating agent Substances 0.000 abstract description 2
- 238000000576 coating method Methods 0.000 abstract description 2
- 230000028993 immune response Effects 0.000 abstract description 2
- 238000012606 in vitro cell culture Methods 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 abstract description 2
- 210000002993 trophoblast Anatomy 0.000 abstract description 2
- 238000001994 activation Methods 0.000 description 16
- 230000003321 amplification Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 2
- 230000006051 NK cell activation Effects 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/71—Oxidoreductases (EC 1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
- C12N2506/025—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells from extra-embryonic cells, e.g. trophoblast, placenta
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
样本1 | 样本2 | 样本3 | |
0天脐血NK细胞纯度 | 5.18% | 5.45% | 4.47% |
14天脐血NK细胞纯度 | 97.93% | 96.51% | 95.88% |
Claims (1)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111208066.6A CN113789299B (zh) | 2021-10-18 | 2021-10-18 | 一种脐血nk细胞的体外增殖培养基、体外培养试剂盒和体外培养方法 |
US17/671,312 US20230123462A1 (en) | 2021-10-18 | 2022-02-14 | In vitro proliferation medium, in vitro culture kit and in vitro proliferation culture method of umbilical cord blood (ucb)-derived natural killer (nk) cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111208066.6A CN113789299B (zh) | 2021-10-18 | 2021-10-18 | 一种脐血nk细胞的体外增殖培养基、体外培养试剂盒和体外培养方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113789299A CN113789299A (zh) | 2021-12-14 |
CN113789299B true CN113789299B (zh) | 2023-03-24 |
Family
ID=78878023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111208066.6A Active CN113789299B (zh) | 2021-10-18 | 2021-10-18 | 一种脐血nk细胞的体外增殖培养基、体外培养试剂盒和体外培养方法 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20230123462A1 (zh) |
CN (1) | CN113789299B (zh) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017046142A1 (en) * | 2015-09-15 | 2017-03-23 | Stichting Katholieke Universiteit | IMPROVED METHOD FOR EX VIVO EXPANSION CD34+HSPCs INTO NK CELLS USING AN ARYL HYDROCARBON RECEPTOR ANTAGONIST |
WO2017133175A1 (en) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
CN107058223A (zh) * | 2017-05-10 | 2017-08-18 | 湖南惠益森细胞基因工程有限公司 | 一种用于免疫细胞培养的培养液 |
CN107384859A (zh) * | 2017-09-05 | 2017-11-24 | 四川新生命干细胞科技股份有限公司 | 一种高纯度nk细胞的分离培养方法 |
WO2020124256A1 (en) * | 2018-12-21 | 2020-06-25 | Stemcell Technologies Canada Inc. | Media and methods for differentiating natural killer cells |
US20210260115A1 (en) * | 2020-02-21 | 2021-08-26 | FullHope Biomedical Co., Ltd. | Modified natural killer cells, pharmaceutical composition, manufacturing method thereof, and method of using the same |
CN113293132A (zh) * | 2021-05-19 | 2021-08-24 | 江苏豪科生物工程有限公司 | 一种nk细胞体外扩增体系及培养方法 |
-
2021
- 2021-10-18 CN CN202111208066.6A patent/CN113789299B/zh active Active
-
2022
- 2022-02-14 US US17/671,312 patent/US20230123462A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230123462A1 (en) | 2023-04-20 |
CN113789299A (zh) | 2021-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112626018A (zh) | 一种高纯度的同种异体nk细胞培养基以及体外扩增方法 | |
CN112608896A (zh) | 一种nk细胞的培养方法及其应用 | |
CN111944754A (zh) | 一种自然杀伤细胞的培养方法 | |
CN109456940A (zh) | 得到nk细胞或树突细胞的方法 | |
JPH08511935A (ja) | 選択的細胞増殖 | |
El-Sahrigy et al. | Comparison between magnetic activated cell sorted monocytes and monocyte adherence techniques for in vitro generation of immature dendritic cells: an Egyptian trial | |
CN113789299B (zh) | 一种脐血nk细胞的体外增殖培养基、体外培养试剂盒和体外培养方法 | |
CN104109653A (zh) | 利用无动物血清培养体系大规模扩增人外周血dnt细胞的方法 | |
CN111172110B (zh) | 一种脐带血cik细胞的培养方法 | |
CN113564117A (zh) | 一种冻存脐带血来源调节性t细胞体外扩增优化方法 | |
CN110938595B (zh) | 一种高效体外培养脐血cik细胞的培养基及培养方法 | |
CN113549595A (zh) | 基于外周血的nk细胞体外培养方法 | |
CN114507640B (zh) | 一种高增殖能力和高细胞毒性cik细胞的培养方法及其应用 | |
CN111548994A (zh) | 一种细胞培养基及其培养nk细胞的方法 | |
CN113481157B (zh) | 特异性抗病毒过继免疫细胞的优化制备方法 | |
CN108148805B (zh) | 一种人Tscm细胞及其制备方法和应用 | |
CN115197909B (zh) | 一种nk细胞的体外培养方法 | |
CN111154721B (zh) | Nk细胞扩增方法 | |
CN112300992B (zh) | 一种nk细胞培养液及多级激活nk细胞的培养方法 | |
CN109576220B (zh) | 一种灭活饲养细胞联合细胞因子刺激nk细胞扩增的方法 | |
CN110964695A (zh) | 一种细胞株及其增殖检测rhIL-12体外活性的方法 | |
CN111088227A (zh) | 一种细胞分离培养液和t细胞分离培养的方法 | |
CN105219710B (zh) | 一种高杀伤活性的免疫细胞群的培养方法 | |
CN113881633B (zh) | 一种脐带血造血干细胞体外干性扩增的培养基及方法 | |
CN114990061B (zh) | 一种诱导扩增中央记忆性t细胞的培养方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220507 Address after: 100050 Tiantan Xili 1, Dongcheng District, Beijing Applicant after: INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES Address before: 102488 no.86-a3764, Wanxing Road, Changyang, Fangshan District, Beijing Applicant before: Zhuoerkang (Beijing) Biotechnology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20221010 Address after: 570100 - 1073, 1st Floor, D2 District, Fuxing City, 32 Binhai Street, Longhua District, Haikou, Hainan Applicant after: Xinlu Cell Biotechnology (Hainan) Co.,Ltd. Address before: 100050 Tiantan Xili 1, Dongcheng District, Beijing Applicant before: INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |